Human Neural Stem Cell Therapy for Chronic Ischemic Stroke: Charting Progress from Laboratory to Patients
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Chronic disability after stroke represents a major unmet neurologic need. ReNeuron's development of a human neural stem cell (hNSC) therapy for chronic disability after stroke is progressing through early clinical studies. A Phase I trial has recently been published, showing no safety concerns and some promising signs of efficacy. A single-arm Phase II multicenter trial in patients with stable upper-limb paresis has recently completed recruitment. The hNSCs administrated are from a manufactured, conditionally immortalized hNSC line (ReNeuron's CTX0E03 or CTX), generated with c-mycERTAM technology. This technology has enabled CTX to be manufactured at large scale under cGMP conditions, ensuring sufficient supply to meets the demands of research, clinical development, and, eventually, the market. CTX has key pro-angiogenic, pro-neurogenic, and immunomodulatory characteristics that are mechanistically important in functional recovery poststroke. This review covers the progress of CTX cell therapy from its laboratory origins to the clinic, concluding with a look into the late stage clinical future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Human mesenchymal stem cells modulate allogeneic immune cell responses
Aggarwal, S., & Pittenger, M. F. (2005) · Blood · doi:10.1182/blood-2004-04-1559 · Cited by 4,511
Neuronal replacement from endogenous precursors in the adult brain after stroke
Arvidsson, A., Collin, T., Kirik, D., Kokaia, Z., & Lindvall, O. (2002) · Nature Medicine · doi:10.1038/nm747 · Cited by 2,799 · cited 2×
“[63] also attributed the decreased neurogenesis to inflammation; however, increased proliferation in the SVZ has also been noted at relatively early time points after injury in the adult brain [48,64,65].”
BackgroundInflammation is detrimental for neurogenesis in adult brain
Ekdahl, C. T., Claasen, J.-H., Bonde, S., Kokaia, Z., & Lindvall, O. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2234031100 · Cited by 1,559
Morshead, C. M., Reynolds, B. A., Craig, C. G., McBurney, M. W., Staines, W. A., Morassutti, D., Weiss, S., & van der Kooy, D. (1994) · Neuron · doi:10.1016/0896-6273(94)90046-9 · Cited by 1,403 · cited 1×
“In the adult rodent brain, the SVZ contains proliferating progenitor cells and relatively quiescent NSCs [62].”
BackgroundVEGF enhances angiogenesis and promotes blood–brain barrier leakage in the ischemic brain
Zhang, Z. G., Zhang, L., Jiang, Q., Zhang, R., Davies, K., Powers, C., Bruggen, N. V., & Chopp, M. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9369 · Cited by 1,296
VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia
Sun, Y., Jin, K., Xie, L., Childs, J., Mao, X. O., Logvinova, A., & Greenberg, D. A. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317977 · Cited by 1,189
Indoleamine 2,3 dioxygenase and metabolic control of immune responses
Munn, D. H., & Mellor, A. L. (2013) · Trends in Immunology · doi:10.1016/j.it.2012.10.001 · Cited by 1,037 · cited 1×
“The enzyme IDO is also activated during inflammation and drives toward conditions that favor immune suppression and tolerance [73].”
BackgroundNeurogenesis in the striatum of the adult human brain
Ernst, A., Alkass, K., Bernard, S., Salehpour, M., Perl, S., Tisdale, J., Possnert, G., Druid, H., & Frisén, J. (2014) · Cell · doi:10.1016/j.cell.2014.01.044 · Cited by 937
A Neurovascular Niche for Neurogenesis after Stroke
Ohab, J. J., Fleming, S., Blesch, A., & Carmichael, S. T. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.4323-06.2006 · Cited by 878
Selective Ablation of Proliferating Microglial Cells Exacerbates Ischemic Injury in the Brain
Lalancette-Hébert, M., Gowing, G., Simard, A., Weng, Y. C., & Kriz, J. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.5360-06.2007 · Cited by 874
Cited by
Sandvig, I., Augestad, I. L., Håberg, A. K., & Sandvig, A. (2018) · European Journal of Neuroscience · doi:10.1111/ejn.13959 · Cited by 94
Practical Use of Immortalized Cells in Medicine: Current Advances and Future Perspectives
Voloshin, N., Tyurin-Kuzmin, P., Karagyaur, M., Akopyan, Z., & Kulebyakin, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612716 · Cited by 77
“Despite some issues with the methodology of clinical trials (small sample size, wide range of time elapsed since stroke, lack of female patients in phase I [44,45]), many preclinical [42,43,46] and clinical studies demonstrate that the CTX0E03 cell line is a promising therapeutic tool with a significant neuroregenerat…”
MethodYoon, Y., Kim, H. S., Jeon, I., Noh, J.-E., Park, H. J., Lee, S., Park, I.-H., Stevanato, L., Hicks, C., Corteling, R., et al. (2020) · Stem Cells · doi:10.1002/stem.3191 · Cited by 34
Self-citation
Metadata
- Authors
- Sinden, J. D., Hicks, C., Stroemer, P., Vishnubhatla, I., & Corteling, R.
- Venue
- Stem Cells and Development
- Publisher
- SAGE Publications
- Published
- 2017-07
- Volume
- 26
- Issue
- 13
- Pages
- 933-947
- ISSN
- 1525-8165 (ISSN-L)
- 1547-3287
- 1557-8534
- OpenAlex
- W2609048210
- Cited by
- 78
- References
- 14
- FWCI
- 5.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Human Neural Stem Cell Therapy for Chronic Ischemic Stroke: Charting Progress from Laboratory to Patients. https://app.cochat.ai/papers/10.1089/scd.2017.0009
- The paper
- Sinden, J. D., Hicks, C., Stroemer, P., Vishnubhatla, I., & Corteling, R. (2017). Human Neural Stem Cell Therapy for Chronic Ischemic Stroke: Charting Progress from Laboratory to Patients. Stem Cells and Development. https://doi.org/10.1089/scd.2017.0009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.